Jasper Therapeutics ($JSPR) Misleading Trial Data and Manufacturing Oversight Case

The court has appointed the lead plaintiff to represent the class.

N.D. California

Court

5:25-cv-08010

Case number

11/30/2023

Class period Start

07/03/2025

Class period End

11/18/2025

Lead Plaintiff motion deadline

$JSPR investors filed a claim against Jasper Therapeutics for misleading investors about the reliability of its clinical trial data, concealing manufacturing issues, and overstating briquilimab’s development prospects.
After Jasper disclosed that clinical trial results were compromised due to faulty drug lots, halted two major programs, and cut 50% of its workforce, $JSPR dropped 55.1% from $6.77 on July 3, 2025, to $3.04 on July 7, 2025.
$JSPR investors can join this case to be notified about potential recovery.
Case Details:

Between November 30, 2023, and July 3, 2025, Jasper Therapeutics told investors that its lead candidate, briquilimab, was progressing successfully through clinical trials targeting mast cell-driven diseases like chronic urticaria and asthma. Management emphasized positive milestones, including rapid patient enrollment, dose escalation, and safety affirmation by the Independent Data Monitoring Committee. Jasper also claimed it had sufficient cash to fund operations through Q3 2025, following a $50M raise in 2024.

However, Jasper failed to disclose that it lacked adequate manufacturing oversight and quality controls to ensure that third-party suppliers followed current Good Manufacturing Practices (cGMP). This raised the risk of invalid trial results and regulatory setbacks.

On July 7, 2025, Jasper revealed that trial data in two dosing cohorts were compromised by a defective drug product lot. Ten of the thirteen patients in those cohorts received the faulty batch, leading to abnormal results. The company also admitted that the same batch was used in its asthma trial and halted that program entirely, along with its SCID study. Management cited the need for cost-cutting and revealed that it would consider a restructuring.

Following this announcement, $JSPR fell 55.1%, from July 3 to July 7, 2025. Analysts downgraded the stock, citing uncertainty, manufacturing risks, and competitive pressures.

Two days later, on July 9, 2025, Jasper announced a major reorganization, halting all non-CSU programs and laying off 50% of its workforce. The company’s Chief Medical Officer resigned.

Based on these events, $JSPR investors filed a claim against Jasper, alleging the company:
Failed to implement proper controls over third-party drug manufacturers.
Misled investors about the reliability of its trial data and financial runway.
Overstated briquilimab’s clinical prospects while concealing manufacturing risks.
Investors argue Jasper misled the market about its operational integrity and the viability of its pipeline, causing major losses when the truth was revealed.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointed

Alleged Offence

Mismanagement,

Misleading Statements,

Failure to Disclose

Suspected Party

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

07/07/2025

Filing date

09/19/2025

Lead Plaintiff Deadline

11/18/2025

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.